PD-L1 Antikörper (C-Term)

Produktnummer ABIN2855940

This anti-PD-L1 antibody (ABIN2855940) is a Rabbit Polyclonal antibody detecting PD-L1 in WB, FACS, ICC, IF, IHC (p), IHC (fro). Suitable for Human.

Kurzübersicht für PD-L1 Antikörper (C-Term) (ABIN2855940)

Target: PD-L1 (CD274 (PD-L1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PD-L1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Flow Cytometry (FACS), Immunocytochemistry (ICC), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Güteklasse: KO Validated

Produktdetails anti-PD-L1 Antikörper

Bindungsspezifität: C-Term

Kreuzreaktivität: Human

Produktmerkmale: Rabbit Polyclonal antibody to PD-L1 (CD274 Molecule)
PD-L1 antibody

Aufreinigung: Purified by antigen-affinity chromatography.

Immunogen: Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human PD-L1. The exact sequence is proprietary.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. Optimal dilutions/concentrations should be determined by the researcher. Not tested in other applications.

Kommentare:

Positive Control: MDA-MB-231 (24μg/ml Tunicamycin treatment for 16 hr) , MDA-MB-231 , A431(100 ng/mL IFN-gamma treatment for 48 hr)

Validation: Comparison, KO/KD, Orthogonal, Overexpression

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.29 mg/mL

Buffer: 1XPBS, 1 % BSA, 20 % Glycerol ( pH 7), 0.025 % ProClin 300

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.

Referenzen für anti-PD-L1 Antikörper (ABIN2855940)

Kim, Kim, Kim, Kim, Kim: "Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder." in: Journal of clinical medicine, Vol. 9, Issue 5, (2020) (PubMed).

Qin, Wang, Ye, Li, Chen, Wang, Qin, Zhang, Li, Long, Hu, Shi, Li, Zhang, Zhai, Tang, Kang, Lan, Xie, Lu, Deng: "NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer." in: Nature communications, Vol. 11, Issue 1, pp. 1669, (2020) (PubMed).

Gondhowiardjo, Handoko, Adham, Rachmadi, Kodrat, Tobing, Haryoga, Dwiyono, Kristian, Mayang Permata: "Tumor microenvironment predicts local tumor extensiveness in PD-L1 positive nasopharyngeal cancer." in: PLoS ONE, Vol. 15, Issue 3, pp. e0230449, (2020) (PubMed).

Pan, Wu, Kan, Li, Chang, Wu, Li, Ou-Yang, Hou, Yip, Luo: "Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer." in: Cancers, Vol. 12, Issue 1, (2019) (PubMed).

Cha, Yang, Xia, Wei, Chan, Lim, Li, Kim, Chang, Lee, Hsu, Wang, Kuo, Chang, Hadad, Purdie, McCoy, Cai, Tu, Litton, Mittendorf, Moulder, Symmans, Thompson, Piwnica-Worms, Chen, Khoo, Hung: "Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1." in: Molecular cell, Vol. 71, Issue 4, pp. 606-620.e7, (2019) (PubMed).

Buisseret, Garaud, de Wind, Van den Eynden, Boisson, Solinas, Gu-Trantien, Naveaux, Lodewyckx, Duvillier, Craciun, Veys, Larsimont, Piccart-Gebhart, Stagg, Sotiriou, Willard-Gallo: "Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer." in: Oncoimmunology, Vol. 6, Issue 1, pp. e1257452, (2017) (PubMed).

Lin, Sung, Hsieh, Tsai, Lai, Yang, Shen, Chen, Lee, Yeh, Chen: "High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma." in: PLoS ONE, Vol. 10, Issue 11, pp. e0142656, (2016) (PubMed).

Details zu PD-L1

Target: PD-L1 (CD274 (PD-L1))

Andere Bezeichnung: CD274 molecule

Hintergrund: Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.

Cellular Localization: Isoform 1: Cell membrane, Single-pass type I membrane protein , Isoform 2: Endomembrane system, Single-pass type I membrane protein

Molekulargewicht: 33 kDa

Gen-ID: 29126

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints